##  [Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma](/us-en/news/media-releases/pivotal-data-novartis-investigational-compound-lde225-show-marked-tumor-responses-advanced-basal-cell-carcinoma-0 "Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma") 

  Jun 01, 2014